Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15044666 | 0.85 | ACHE (0.33) | ALDH1A1LMNAHSD17B10ACHE | |
| SCHEMBL19564952 | 0.82 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL19564951 | 0.79 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL22479770 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10TSHRRAB9A | |
| SCHEMBL15044669 | 0.74 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL12971915 | 0.74 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL14627793 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL3199088 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL697625 | 0.74 | — | — | |
| SCHEMBL10171465 | 0.73 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10TSHRCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20180221372-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170320826-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | ENDOCYTE INC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170290920-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | MEDIMMUNE LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130203680-A1 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE | ENDOCYTE, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130158271-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | VLAHOV IONTCHO RADOSLAVOV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | LEAMON CHRISTOPHER PAUL (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120258905-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885LMNA 2066/4885HSD17B10 2817/4885 |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | ALDH1A1 1932/4885LMNA 2529/4885HSD17B10 4195/4885 |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | TEK, TEKT1, CD2BP2 | ALDH1A1 4745/4885LMNA 2494/4885HSD17B10 3551/4885 |
| US-20120258905-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | VDR, HCAR1, CYP2R1 | ALDH1A1 885/4885LMNA 1114/4885HSD17B10 413/4885 |
| US-10010618-B2 | Methods for treating cancer using combination therapies | SLC7A11, CXCR2, TPX2 | ALDH1A1 831/4885LMNA 4453/4885HSD17B10 1231/4885 |
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | VDR, CD44, HCAR1 | ALDH1A1 516/4885LMNA 1724/4885HSD17B10 1662/4885 |
| US-20170290920-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | CD22, CD2, CD2BP2 | ALDH1A1 260/4885LMNA 4493/4885HSD17B10 2456/4885 |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2748/4885LMNA 2077/4885HSD17B10 2833/4885 |
| US-20180221372-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | VDR, HCAR1, CYP2R1 | ALDH1A1 885/4885LMNA 1114/4885HSD17B10 413/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | ALDH1A1 1936/4885LMNA 2374/4885HSD17B10 2716/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885LMNA 2066/4885HSD17B10 2817/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885LMNA 2066/4885HSD17B10 2817/4885 |
| US-20130158271-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | PAICS, FOLR2, DCLRE1A | ALDH1A1 2328/4885LMNA 1496/4885HSD17B10 2411/4885 |
| US-20130203680-A1 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE | FOLR2, FOLR1, DHFR | ALDH1A1 336/4885LMNA 4069/4885HSD17B10 1582/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885LMNA 2066/4885HSD17B10 2817/4885 |
| US-20170320826-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | PAICS, FOLR2, DCLRE1A | ALDH1A1 2328/4885LMNA 1496/4885HSD17B10 2411/4885 |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | FOLR1, FOLR2, DHFR | ALDH1A1 1044/4885LMNA 3893/4885HSD17B10 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.